CRUK teams up with Teon to trial first-in-class cancer drug
Cancer Research UK (CRUK) has signed a clinical development collaboration with California-based Teon Therapeutics.
March 3, 2021
by pharmaceutical-technology
Oscotec and Beactica Therapeutics announce license and collaboration agreement to develop new cancer drug
Oscotec Inc., the Korean drug development company, and Beactica Therapeutics AB, the Swedish drug discovery company, today announced a new research development and licensing agreement.
March 2, 2021
by prnasia
Researchers from IIT Madras identify alternative source for anti-cancer drug Camptothecin
At present, this drug is sourced from Chinese and Indian tree species, which are now critically endangered due to extensive overharvesting to meet the market demand.
February 26, 2021
by expresspharma
Fresenius Kabi Oncology Ltd to pay $50mn for destroying records ahead of an FDA Inspection
The Indian drug company pleaded guilty to concealing and destroying records containing evidence of its Kalyani plant manufacturing drugs in contravention to FDA requirements prior to a 2013 inspection.
February 19, 2021
by europeanpharmaceuticalreview
Celleron picks up discarded cancer drug from Roche
Oxford, UK-based Celleron Therapeutics has signed a licensing agreement with Roche for exclusive rights to emactuzumab, a monoclonal antibody and tumour microenvironment modulator.
August 14, 2020
by pharmatimes
ICR/Cyclacel scientists discover new cancer drug
Researchers say they have discovered a new cancer drug with potential use against a range of cancers, including some blood cancers and solid tumours.
July 16, 2020
by pharmatimes
Roche signs up to $1.7bn cancer drug deal with Blueprint Medicines
Roche has entered into a licensing and collaboration agreement with Blueprint Medicines for exclusive rights to co-develop and commercialise the latter’s cancer drug, pralsetinib, outside the US, except in Greater China.
July 15, 2020
by pharmaceutical-technolog
Ruxolitinib to be studied as COVID-19 treatment in clinical trial
Following the successful treatment of a COVID-19 patient with ARDS using ruxolitinib, Germany is set to begin clinical trials to test the drug.
June 24, 2020
by europeanpharmaceuticalreview
“Precise” “Broad-spectrum” – An Overview of NTRK Fusion-Targeted Oncology Drugs
According to the official website of the CDE recently, InnoCare Pharma’s ICP-723 tablets has received a clinical trial implied permission,
June 17, 2020
by PharmaSources/Zongqin
How a Seattle Genetics cancer drug could help lupus patients
The kidney is often a target of autoimmune diseases, including lupus. But little is known about how immune cells adapt to the low oxygen level in renal tissue to wreak havoc.
April 13, 2020
by fiercebiotech
BeiGene obtains certain rights for Leap Therapeutics’ cancer drug
Chinese biopharmaceutical firm BeiGene has agreed to exclusive rights to develop and commercialise Leap Therapeutics’ cancer drug DKN-01 in the Asia Pacific region, excluding Japan.
January 7, 2020
by pharmaceutical-technology
BeiGene cancer drug misses mark in Phase III study
BeiGene Announces Results of Phase 3 ASPEN Trial of Zanubrutinib Compared to Ibrutinib for the Treatment of Patients with Waldenström’s Macroglobulinemia
December 22, 2019
by biospectrumasia